Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ECO-RESET: A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Study to Assess Efficacy and Safety of SER‑287 in Adults With Active Mild-to-Moderate Ulcerative Colitis

Trial Profile

ECO-RESET: A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Study to Assess Efficacy and Safety of SER‑287 in Adults With Active Mild-to-Moderate Ulcerative Colitis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Jan 2019

At a glance

  • Drugs SER 287 (Primary) ; Vancomycin
  • Indications Ulcerative colitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Seres Therapeutics
  • Most Recent Events

    • 28 Nov 2018 Status changed from planning to recruiting.
    • 28 Nov 2018 Planned number of patients changed from 200 to 201.
    • 08 Nov 2018 According to a Seres Therapeutics media release, the company has designed this study as a potentially pivotal trial, and is awaiting feedback from the FDA on this final study design.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top